ICER Boosts ‘Cost-Recovery’ Benchmark Price For Remdesivir To Reflect Gilead’s Planned R&D

But updated pricing model also suggests the more traditional ‘cost effectiveness’ benchmark price for remdesivir could be lower than previously estimated to account for use of dexamethasone in reducing the underlying risk of mortality in COVID-19 patients.